Patent intelligence · US
US 11110178
Antibody adjuvant conjugates
Antibody adjuvant conjugates
Patent details — US 11110178
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 7, 2021
- Expiration
- Sep 2, 2041
- Applicant
- Bolt Biotherapeutics, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K2039/55511, A61K2039/55516, A61K2039/5555
Quick answer
US 11110178 (Antibody adjuvant conjugates) is held by Bolt Biotherapeutics, Inc.. Status: granted. Granted Sep 7, 2021. Expires Sep 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bolt Biotherapeutics, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K2039/55511, A61K2039/55516, A61K2039/5555, A61K2039/55561, A61K2039/55572
More from Bolt Biotherapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12325750
Anti-Dectin-2 antibodies and methods of using
granted -
US 11753474
Anti-Dectin-2 antibodies
granted -
US 11654199
Thienoazepine immunoconjugates, and uses thereof
granted -
US 11547761
Antibody adjuvant conjugates
granted -
US 11400164
Immunoconjugates targeting HER2
granted -
US 10675358
Antibody adjuvant conjugates
granted
Frequently asked questions
What is US patent 11110178?
US 11110178 (Antibody adjuvant conjugates) is held by Bolt Biotherapeutics, Inc.. Status: granted. Granted Sep 7, 2021. Expires Sep 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11110178?
Bolt Biotherapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11110178 expire?
Our index shows an expiration date of Sep 2, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.